Budget Impact Analysis of Lebrikizumab for Treating Severe Atopic Dermatitis
Abstract Introduction Lebrikizumab is a novel monoclonal antibody that targets interleukin-13, a pivotal factor in atopic dermatitis (AD). Previous studies revealed a positive benefit–risk profile of lebrikizumab as treatment for patients with moderate-to-severe AD. In Italy, lebrikizumab has been a...
Salvato in:
| Autori principali: | , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Adis, Springer Healthcare
2025-07-01
|
| Serie: | Dermatology and Therapy |
| Soggetti: | |
| Accesso online: | https://doi.org/10.1007/s13555-025-01475-2 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|